Aurobindo's injectable business grows 8% year-on-year to $50 mn in Q2

Analysts feel R&D costs are set to rise as a result of injectables and biosimilars focus

from Latest News http://bit.ly/2Q1DpRG
https://ift.tt/eA8V8J http://bit.ly/2SdCH5P

• Tweet
• Share
• Share
• Share
• Share